Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Resistance Research
• Drug Interaction Studies

Background:

• Vancomycin is a critical antibiotic for treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
• Interactions between antibiotics and other medications can lead to synergistic or antagonistic effects, impacting treatment efficacy.
• Understanding these interactions is crucial for optimizing MRSA infection management.

Purpose of the Study:

• To screen a large library of pharmacological agents for their ability to modulate MRSA susceptibility to vancomycin.
• To identify non-antibiotic compounds that exhibit synergistic or additive effects when combined with vancomycin.
• To investigate the mechanisms and clinical implications of such drug interactions.

Main Methods:

• A library of 1237 compounds was screened in combination with vancomycin against MRSA.
• Caspofungin and tolcapone were further analyzed using checkerboard assays and flow cytometry.
• Minimum inhibitory concentrations (MICs) were determined to assess antibacterial activity and drug effects.

Main Results:

• Seventeen non-antibiotic compounds, including caspofungin and tolcapone, showed synergistic or additive potential with vancomycin.
• Caspofungin demonstrated additive effects in increasing MRSA cell death when combined with vancomycin.
• Tolcapone exhibited bacteriostatic properties and appeared to inhibit vancomycin's bactericidal action.

Conclusions:

• Non-antibiotic medications can significantly alter the pharmacodynamic properties of vancomycin.
• These findings have potential clinical implications for patients with MRSA infections who are concurrently treated for other conditions.
• Further research is warranted to explore the therapeutic potential of these drug combinations.